Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Bayer
Robert G Hart; Mukul Sharma; Hardi Mundl; Scott E Kasner; Shrikant I Bangdiwala; Scott D Berkowitz; Balakumar Swaminathan; Pablo Lavados; Yongjun Wang; Yilong Wang; Antonio Davalos; Nikolay Shamalov; Robert Mikulik; Luis Cunha; Arne Lindgren; Antonio Arauz; Wilfried Lang; Anna Czlonkowska; Jens Eckstein; Rubens J Gagliardi; Pierre Amarenco; Sebastian F Ameriso; Turgut Tatlisumak; Roland Veltkamp; Graeme J Hankey; Danilo Toni; Daniel Bereczki; Shinichiro Uchiyama; George Ntaios; Byung-Woo Yoon; Raf Brouns; Matthias Endres; Keith W Muir; Natan Bornstein; Serefnur Ozturk; Martin J O'Donnell; Matthys M De Vries Basson; Guillaume Pare; Calin Pater; Bodo Kirsch; Patrick Sheridan; Gary Peters; Jeffrey I Weitz; W Frank Peacock; Ashkan Shoamanesh; Oscar R Benavente; Campbell Joyner; Ellison Themeles; Stuart J Connolly